The four main approaches to immunisation against hepatitis B are: vaccination of high risk babies; universal adolescent immunisation; universal infant immunisation; and vaccination of everybody. Universal antenatal screening would permit identification of carrier mothers and immunisation oftheir babies. Vaccination of adolescents would provide protection close to the time when risk of exposure increases, and could be delivered as part of a wider package on health education. Universal vaccination ofinfants is the best option because it is known that vaccines can be delivered to babies and it is more acceptable to parents. Development of a combined hepatitis B-diphtheria-pertussis-tetanus vaccine would be beneficial. The identification of hepatitis B antibody escape mutants is of concern because of the implications for vaccine efficacy. Altered or absent expression ofthe hepatitis B virus (HBV) antigenic group determinant a may allow infection even in subjects who have responded previously to vaccination.
Although hepatitis B is a public health problem throughout the world and is preventable, a consensus on immunisation strategies is notable by its absence. Current policies in many There are several problems with this approach, including the following: * Persuading parents to accept vaccination of their children against an infection that is also transmitted by the sexual route may not be easy, and may well be a problem they do not wish to consider at that time; * Ensuring that a full course of three doses is given may be difficult; * There would be difficulty evaluating and monitoring vaccine cover. The systems for monitoring uptake of vaccine in this age group may not operate efficiently. Production of antibodies to epitope a mediates cross protection against all hepatitis B virus (HBV) subtypes, as has been shown by challenge with a second subtype of the virus after recovery from an initial experimental infection. The epitope a is located in the region of amino acids 124-148 of the major surface protein, and seems to have a double loop conformation. A monoclonal antibody that recognises a region within this a epitope is capable of neutralising the infectivity of HBV, and competitive inhibition assays using the same monoclonal antibody show that equivalent antibodies are present in the sera of subjects immunised with either plasma derived or recombinant hepatitis B vaccine.
During a study of the immunogenicity and efficacy of hepatitis B vaccines in Italy, a number of subjects who had apparently mounted a successful immune response to the surface antigen of the virus (that is, became anti-HBs positive) later became infected with HBV. These cases were characterised by the coexistence of non-complexed anti-HBs and hepatitis B surface antigen (HBsAg) and, in 32 of 44 vaccinated subjects, there were other markers of HBV replication.2 Furthermore, analysis of the antigen using monoclonal antibodies suggested that the a epitope was either absent or masked by antibody. Subsequent sequence analysis of the virus from one of these cases showed a mutation in the nucleotide sequence encoding the a epitope, the consequence of which was a substitution of arginine for glycine at amino acid position 145.3
The region in which this mutation occurs is an important virus epitope to which vaccine induced neutralising antibody binds, as discussed above. The mutant virus is not neutralised by antibody to this specificity. It can replicate as a competent virus, implying that the amino acid substitution does not change the attachment of the virus to the liver cell. This has been confirmed in experimental transmission studies at the National Institutes of Health in the USA.4
GEOGRAPHICAL DISTRIBUTION
There is now considerable evidence for a wide geographical distribution of the point mutation in HBV from guanosine to adenosine at position 587, resulting in an amino acid substitution at position 145 from glycine to arginine in the highly antigenic group determinant a of the surface antigen. This stable mutation has been found in viral isolates from children several years later and it has been described in Italy, Singapore, Japan, and Brunei.5 It has also been found in liver transplant recipients with hepatitis B in the United States, Germany, and the United Kingdom who had been treated with specific hepatitis B immunoglobulin or humanised hepatitis B monoclonal antibody.5
During a study in progress in Singapore, three groups of babies were immunised against hepatitis B: 50 babies born to mothers without HBsAg and 600 born to mothers with HBsAg but without hepatitis B e antigen (HBeAg) were immunised successfully. However, among the 600 babies born to mothers with HBsAg and HBeAg, there were 40 vaccine failures, and all were positive for HBsAg and core antibody. Direct sequencing has been completed for 26 isolates from these 40 infants. Fifteen had wild type sequences, and serological profiles usually indicated in utero infection. However, the other 11 had variant sequencesnamely, the 145 glycine to arginine variant alone (four cases) or with alanine at position 144 (in one twin), or other changes yet to be evaluated.6
Variants of HBV with altered antigenicity of the envelope protein show that this virus is not as antigenically singular as previously believed and that humoral escape mutation can occur in vivo. There are two important causes for concern: firstly, failure to detect HBsAg may lead to HBV transmission through donated blood or organs; secondly, the mutated HBV may infect subjects who are anti-HBs positive after immunisation. Mutants, variants, altered genotypes, and unusual strains are now being sought in many laboratories. The emergence of escape mutants may necessitate the modification of currently available hepatitis B vaccines and the design of new hepatitis B vaccines.
